MTNB Matinas BioPharma Holdings Inc

Price (delayed)

$0.802

Market cap

$5.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.99

Enterprise value

$3.93M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 45
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 10

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has ...

Highlights
Matinas BioPharma Holdings's debt has shrunk by 56% YoY and by 12% QoQ
The EPS has soared by 50% YoY
The company's net income rose by 47% YoY but it fell by 2.6% QoQ
The company's quick ratio has shrunk by 63% YoY and by 58% QoQ
The company's equity has shrunk by 52% YoY and by 37% QoQ

Key stats

What are the main financial stats of MTNB

MTNB stock price

How has the Matinas BioPharma Holdings stock price performed over time
Intraday
3.08%
1 week
0.94%
1 month
19.7%
1 year
-3.39%
YTD
36.86%
QTD
60.4%

Financial performance

How have Matinas BioPharma Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$6.91M
Net income
-$10.61M
Gross margin
N/A
Net margin
N/A
The operating income has soared by 66% YoY
The company's net income rose by 47% YoY but it fell by 2.6% QoQ

Price vs fundamentals

How does MTNB's price correlate with its fundamentals

Growth

What is Matinas BioPharma Holdings's growth rate over time

Valuation

What is Matinas BioPharma Holdings stock price valuation
P/E
N/A
P/B
1.7
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 50% YoY
The stock's price to book (P/B) is 65% more than its last 4 quarters average of 1.0 but 31% less than its 5-year quarterly average of 2.4
The company's equity has shrunk by 52% YoY and by 37% QoQ

Efficiency

How efficient is Matinas BioPharma Holdings business performance
Matinas BioPharma Holdings's ROIC has decreased by 31% YoY and by 22% from the previous quarter
The ROE is down by 24% year-on-year and by 18% since the previous quarter
The return on assets has declined by 21% since the previous quarter and by 14% year-on-year

Dividends

What is MTNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MTNB.

Financial health

How did Matinas BioPharma Holdings financials performed over time
Matinas BioPharma Holdings's total assets is 106% higher than its total liabilities
The company's quick ratio has shrunk by 63% YoY and by 58% QoQ
MTNB's current ratio has dropped by 61% year-on-year and by 53% since the previous quarter
Matinas BioPharma Holdings's debt is 61% lower than its equity
Matinas BioPharma Holdings's debt has shrunk by 56% YoY and by 12% QoQ
The company's equity has shrunk by 52% YoY and by 37% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.